



# LUND UNIVERSITY

## Prevention of domain swapping inhibits dimerization and amyloid fibril formation of cystatin C

use of engineered disulfide bridges, antibodies, and carboxymethylpapain to stabilize the monomeric form of cystatin C

Wahlbom, Maria; Wang, Xin; Rodziewicz-Motowidlo, Sylwia; Janowski, Robert; Lindström, Veronica; Önerfjord, Patrik; Westermark, Gunilla; Grzonka, Zbigniew; Jaskolski, Mariusz; Grubb, Anders

*Published in:*

Journal of Biological Chemistry

*DOI:*

[10.1074/jbc.M402621200](https://doi.org/10.1074/jbc.M402621200)

2004

[Link to publication](#)

*Citation for published version (APA):*

Wahlbom, M., Wang, X., Rodziewicz-Motowidlo, S., Janowski, R., Lindström, V., Önerfjord, P., Westermark, G., Grzonka, Z., Jaskolski, M., & Grubb, A. (2004). Prevention of domain swapping inhibits dimerization and amyloid fibril formation of cystatin C: use of engineered disulfide bridges, antibodies, and carboxymethylpapain to stabilize the monomeric form of cystatin C. *Journal of Biological Chemistry*, 279(23), 24236-24245. <https://doi.org/10.1074/jbc.M402621200>

*Total number of authors:*

10

### General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00

# Prevention of Domain Swapping Inhibits Dimerization and Amyloid Fibril Formation of Cystatin C

USE OF ENGINEERED DISULFIDE BRIDGES, ANTIBODIES, AND CARBOXYMETHYLPAPAIN TO STABILIZE THE MONOMERIC FORM OF CYSTATIN C\*

Received for publication, March 8, 2004, and in revised form, March 16, 2004  
Published, JBC Papers in Press, March 17, 2004, DOI 10.1074/jbc.M402621200

Maria Nilsson‡§, Xin Wang‡§, Sylwia Rodziewicz-Motowidlo¶, Robert Janowski||,  
Veronica Lindström‡, Patrik Önerfjord\*\*, Gunilla Westermark‡‡, Zbigniew Grzonka¶,  
Mariusz Jaskolski||, and Anders Grubb‡§§

From the ‡Department of Clinical Chemistry, University Hospital, S-22185 Lund, Sweden, the \*\*Department of Cell and Molecular Biology, University of Lund, S-22184 Lund, Sweden, the ¶Department of Organic Chemistry, Faculty of Chemistry, University of Gdansk, J. Sobieskiego 18, 80-952 Gdansk, Poland, the ‡‡Department of Cell Biology, Linköping University, S-58183 Linköping, Sweden, and the ||Department of Crystallography, Faculty of Chemistry, A. Mickiewicz University and Center for Biocrystallographic Research, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Grunwaldzka 6, 60-780 Poznan, Poland

Amyloidogenic proteins like cystatin C and prion proteins have been shown to form dimers by exchange of subdomains of the monomeric proteins. This process, called “three-dimensional domain swapping,” has also been suggested to play a part in the generation of amyloid fibrils. One variant of cystatin C, L68Q cystatin C, is highly amyloidogenic, and persons carrying the corresponding gene suffer from massive cerebral amyloidosis leading to brain hemorrhage and death in early adult life. The present work describes the production of two variants of wild type and L68Q cystatin C with disulfide bridges at positions selected to inhibit domain swapping without affecting the biological function of the four cystatin C variants as cysteine protease inhibitors. The capacity of the four variant proteins to form dimers was tested and compared with that of wild type and L68Q cystatin C. In contrast to the latter two proteins, all four protein variants stabilized by disulfide bridges were resistant toward the formation of dimers. The capacity of the two stabilized variants of wild type cystatin C to form amyloid fibrils was investigated and found to be reduced by 80% compared with that of wild type cystatin C. In an effort to investigate whether exogenous agents could also suppress the formation of dimers of wild type and L68Q cystatin C, a monoclonal antibody or carboxymethylpapain, an inactivated form of a cysteine protease, was added to systems inducing dimerization of wild type and L68Q cystatin C. It was observed that catalytic amounts of both the monoclonal antibody and carboxymethylpapain could suppress dimerization.

Human cystatin C is a low molecular mass protein (13,343 Da, 120 amino acids) belonging to the cystatin superfamily of reversible inhibitors of cysteine proteases of the papain and legumain families (1). Cystatin C is produced by all nucleated human cells and is present in all body fluids (1). Human cystatin C plays an important role in the development of cerebral hemorrhage in patients with a hereditary form of amyloid angiopathy (hereditary cystatin C amyloid angiopathy), where a leucine 68 to glutamine variant of cystatin C (L68Q cystatin C) is deposited as amyloid fibrils in the cerebral arteries, resulting in brain hemorrhage and death in young adults (2). The commonly occurring normal variant of cystatin C (wt<sup>1</sup> cystatin C) also participates in the formation of amyloid depositions together with the amyloid  $\beta$  peptide (A $\beta$ ), particularly in elderly individuals and in patients suffering from Alzheimer’s disease or Down’s syndrome (2, 3). Whereas L68Q cystatin C undergoes dimerization and oligomerization *in vitro* at the temperature of the human body, and is also found in dimeric form *in vivo*, wt cystatin C shows higher stability (4, 5). However, wt cystatin C can also be dimerized *in vitro* at elevated temperature, at low pH, and at conditions of mild chemical denaturation (6). The crystal structure of wt cystatin C (7) showed dimer formation via the mechanism of three-dimensional domain swapping (8), and this observation has led to the suggestion that an analogous three-dimensional domain swapping process, but propagated in an open-ended fashion, could be the basis of the formation of cystatin C amyloid fibrils (7, 9). Dimerization via three-dimensional domain swapping has also been demonstrated in another amyloidogenic protein, the human prion protein (10), and recently, in a series of ingenious experiments, Lee and Eisenberg (11) have given indirect evidence that exchange of structural domains may, indeed, be involved in the aggregation of the prion protein into fibrillar form.

The general fold of monomeric inhibitors of the cystatin superfamily has been defined by the crystal structure of chicken cystatin (12). It consists of a long  $\alpha$ -helix running across a large five-stranded antiparallel  $\beta$ -sheet ( $\beta$ 1– $\beta$ 5). Native cystatin C contains four disulfide-paired cysteine residues, all in the C-terminal part of its sequence (Cys-73–Cys-83, Cys-

\* This work was supported by Project 05196 of the Swedish Science Research Council; by grants from the Medical Faculty of the University of Lund, A. Pahlsson’s, A. Österlund’s, and G. and J. Kock’s Foundations; by Grant 4 T09A 039 25 from the Polish State Committee for Scientific Research; and by a subsidy from the Foundation for Polish Science (to M. J.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This paper is dedicated to Professor David Eisenberg, to celebrate his 65th birthday, and the 10th anniversary of the term “three-dimensional domain swapping.”

§ These authors contributed equally to the present work.

§§ To whom correspondence should be addressed. Tel.: 46-46173964; Fax: 46-46130064; E-mail: anders.grubb@klinkem.lu.se.

<sup>1</sup> The abbreviations used are: wt, wild type; A $\beta$ , amyloid  $\beta$  peptide; PBS, phosphate-buffered saline; OD, optical density.

TABLE I  
Cystatin C variants investigated in the present study

Mutations	Location of disulfide bond	wt cystatin C	L68Q cystatin C
L47C/G69C F29C/M110C	$\beta$ 2 to $\beta$ 3 $\alpha$ to $\beta$ 5	wt cystatin C wt cystatin C stab1 wt cystatin C stab2	L68Q cystatin C L68Q cystatin C stab1 L68Q cystatin C stab2

97–Cys-117). The symmetric dimer of wt cystatin C retains the secondary structure elements of the monomeric form but exchanges them between the two monomer-mimicking subunits. The domain that undergoes swapping consists of the  $\alpha$ -helix and its two flanking  $\beta$ -strands ( $\beta$ 1 and  $\beta$ 2). It is connected to the C-terminal part of the protein (strands  $\beta$ 3– $\beta$ 5) by a hinge region that in the monomeric molecule forms a  $\beta$ -hairpin loop. The native cysteine bridges, both located in the C-terminal part of the protein, do not interfere with the domain swapping process, in which the N- and C-terminal parts are exchanged. Although the crystal structure of L68Q cystatin C has not been determined yet, it is most likely very similar to that of wt cystatin C (13). The crystallographic model of the wt cystatin C dimer explains why the mutated protein is less stable and undergoes domain swapping dimerization much more easily (7). Because the altered residue is located in the central strand ( $\beta$ 3) of the  $\beta$ -sheet and is covered by the  $\alpha$ -helix, where it occupies a hydrophobic pocket formed by residues Val-31 and Tyr-34, the longer and hydrophilic glutamine side chain causes destabilization of the molecular  $\alpha/\beta$  interface, leading to structural rearrangements and increased probability of partial unfolding. In the unfolded state, the newly exposed Gln-68 residue has favorable (as opposed to Leu-68) solvent contacts, thus further contributing to the loss of stability.

Considering the proposed model of fibrillogenesis by propagated three-dimensional domain swapping, it seems possible that inhibition of the domain swapping process should also suppress the entire process of dimerization and fibrillogenesis. The objective of the present work has been to produce two variants of both wt and L68Q cystatin C with disulfide bridges at positions selected to inhibit domain swapping without affecting the biological function of the four cystatin C variants and to investigate whether this would result in suppression of dimerization and fibril formation. In additional experiments investigating whether exogenous agents could also inhibit the formation of dimers of wt and L68Q cystatin C, a monoclonal antibody and carboxymethylpapain were tested and both were shown to suppress the dimerization process.

#### EXPERIMENTAL PROCEDURES

Oligonucleotides were obtained from DNA Technology (Aarhus, Denmark). Restriction endonucleases were purchased from MBI Fermentas (Vilnius, Lithuania). For DNA sequencing, the ABI PRISM BigDye Terminator version 3.0 cycle sequencing kit (Applied Biosystems, Warrington, United Kingdom) was used. Q-Sepharose, Superdex HR75, and CNBr-activated Sepharose were all from Amersham Biosciences (Uppsala, Sweden). Centrifugal microconcentrators were purchased from Amicon (Bedford, MA). The QuikChange Multi site-directed mutagenesis kit was obtained from Stratagene (La Jolla, CA). NuPage gels were purchased from Invitrogen. Agarose (SeaKem LE) was obtained from BioWhittaker Molecular Applications (Rockland, ME). Enzyme substrates were acquired from Bachem Feinchemikalien (Bubendorf, Switzerland). Brij-35 was obtained from Kebo (Stockholm, Sweden). Polyclonal rabbit antibodies against wt cystatin C were obtained from Dakocytomation (Copenhagen, Denmark). Unless specified, all other chemicals used were of analytical grade and obtained from Sigma.

**Construction of Expression Vectors by Site-directed Mutagenesis**—A modified cDNA encoding human cystatin C and the *Escherichia coli* OmpA signal peptide has earlier been used to construct expression plasmids for production of wt cystatin C (14, 15) and L68Q cystatin C (4) in *E. coli* MC1061. The vector pH313, encoding wt cystatin C, was subjected to site-directed mutagenesis by using a QuikChange kit. PCR

amplifications were performed in a PerkinElmer Gene Amp PCR System 2400. The mutated plasmids (named after the corresponding point mutation, e.g. L47C) were verified by restriction analysis because the different primers were designed to either introduce or delete a restriction site. To establish the point mutations L47C and G69C, producing wt cystatin C stab1 (see Fig. 1 and Table I for explanation of the different cystatin C variants investigated in this study), the primers used were L47C (5'-CATGTACCACAGCCGCGCTGCCAGGTGGTGC-GCG-3'), with loss of a PstI recognition site, and G69C (5'-TTCTTG-GACGTGGAGCTGTGCCGAACCACGTGTAC-3'), with a BsuRI site removed. (The underlined residues are the mismatched nucleotides.) The second stabilized variant (wt cystatin C stab2) was produced by introducing the mutations F29C and M110C by the oligonucleotides F29C (5'-TGCAGTGGACTGCGCCGTCGCGAG-3'), containing a new Hin6I recognition site, and M110C (5'-TTGGCAGGGCACATGCACCT-TGTCGAAATCCACC-3'), with the unique PstI site lost. Thereafter, the two different plasmids constructed (L47C/G69C and F29C/M110C) were used as templates to introduce the third point mutation L68Q, with an AluI site removed, using the primers L68Q (5'-TCTTGGAGC-TGGAGCAGGGCCGAACCACGTGTAC-3') and L68Q/G69C (5'-TTCTT-GGACGTGGAGCAGTGCAGAACACGTGTAC-3'). The four generated plasmids (L47C/G69C, F29C/M110C, L47C/L68Q/G69C, and F29C/L68Q/M110C) were verified by sequencing, using primers hybridizing to sequences flanking the genes encoding the signal peptide and the cystatin C variants and primers hybridizing to sequences closer to each other. The primers used were MA097 (5'-CGGCGAGTACAACAAGC-CA-3'), MA098 (5'-CACAGCGTAGATCTGGAAG-3'), MA206 (5'-GT-TTCGCTGTCTGTTTGC-3'), and MA220 (5'-CGACGTTGTAACAC-GACGGC-3'). The sequencing reactions were accomplished by 25 incubation cycles of 10 s at 96 °C, 5 s at 50 °C, and 4 min at 60 °C, and the products were purified by QIAquick nucleotide removal kit (Qiagen, Hilden, Germany). Sequence reaction products were analyzed on an ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA). The verified expression vectors were finally introduced (18) into *E. coli* MC1061 (19).

**Expression of the Cystatin C Variants in *E. coli***—The six cystatin C variants (Table I and Fig. 1) were expressed in *E. coli* MC1061 and purified as described elsewhere (4, 14). Because the expression is under control of the temperature-regulated phage  $\lambda$  cI repressor and  $P_R$  promoter (15), conditions for induction of protein expression from different bacterial subclones were optimized, concerning time, temperature, and culture density. As described for wt cystatin C (14, 15), the expression of wt cystatin C stab1 was induced at 42 °C during 3 h when the optical density (OD) at 600 nm was approximately 5. Wild type cystatin C stab2 was expressed at 38 °C instead of at 42 °C. The *E. coli* system expressing L68Q cystatin C stab1 was diluted to an OD of 3, and the same conditions as those used for expression of wt cystatin C were then applied. L68Q cystatin C and L68Q cystatin C stab2 were both expressed at 38 °C during 2 h at an OD of ~3. From two 450-ml cultures of each bacterial subclone, a total volume of 20 ml of periplasmic extract was obtained by cold osmotic shock (15).

**Isolation of the Cystatin C Variants**—Isolation of the cystatin C variants from periplasmic extracts was accomplished by a previously described two-step procedure (4, 14, 20). Wild type cystatin C, wt cystatin C stab1, and wt cystatin C stab2 were purified by anion exchange chromatography using Q-Sepharose in 20 mM ethanolamine, pH 9.0, containing 1 mM benzamminium chloride. After concentration by ultrafiltration, the samples were subjected to gel chromatography using an Amersham Biosciences FPLC Superdex HR 75 column and 10 mM sodium phosphate buffer, pH 7.4, containing 140 mM sodium chloride, 3 mM potassium chloride, and 1 mM benzamminium chloride (PBS). The solutions of isolated proteins were concentrated to ~0.5 mg/ml by ultrafiltration and stored frozen at -20 °C until used.

The isolation procedure for L68Q cystatin C, L68Q cystatin C stab1, and L68Q cystatin C stab2 comprised binding to a monoclonal antibody raised against wt cystatin C (21) and coupled to CNBr-activated Sepharose. The proteins were eluted with 0.1 M ammonium bicarbonate containing 6 M guanidinium chloride (4) and then subjected to further

purification and buffer exchange by gel chromatography on a Superdex HR 75 column as described above. The solutions of L68Q cystatin C and L68Q cystatin C stab1 were finally concentrated to ~0.2 mg/ml by ultrafiltration, whereas the final concentration of L68Q cystatin C stab2 was approximately 0.05 mg/ml. The L68Q cystatin C variants were stored at 4 °C until used. The protein concentrations of the solutions of the cystatin C variants were determined by UV absorption spectroscopy at 280 nm using a molar extinction coefficient of  $\epsilon = 11,100 \text{ M}^{-1} \text{ cm}^{-1}$  ( $A_{280, 0.1\%} = 0.83$ ) (22).

The isolated cystatin C variants were characterized by agarose gel electrophoresis at pH 8.6 (23) and by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (24) using precast NuPage gradient gels (4–12%) and the morpholinoethansulfonate buffer system at pH 6.4 described by the manufacturer. To verify the identity of protein bands after agarose gel electrophoresis, immunofixation (25) with polyclonal antibodies against wt cystatin C was performed.

**Analysis of Disulfide Bridge Topology**—The positions of the disulfide bridges in wt cystatin C, wt cystatin C stab1, wt cystatin C stab2, and L68Q cystatin C were determined by mass spectrometry. The instrument was a matrix-assisted laser desorption time-of-flight mass spectrometer (Reflex III, Bruker Daltonics, Bremen, Germany). The samples (1–2  $\mu\text{g}$ ) were digested with 40 ng of sequencing grade trypsin (Promega, Madison, WI) in 25 mM ammonium bicarbonate at pH 7.8 for 12 h. The digestion buffer also contained 2 mM *N*-ethylmaleimide (MP Biomedicals, Irvine, CA) to avoid reshuffling of the cysteine bridges. After acidification with trifluoroacetic acid, a short purification step was made on  $\text{C}_{18}$  ZipTips™ (Millipore, Bedford, MA) before direct elution onto the sample target. Approximately 2  $\mu\text{g}$  of matrix, 2,5-dihydroxybenzoic acid, was deposited on the Anchorchip™ (Bruker Daltonics, Bremen, Germany) target plate before sample was applied. The analysis was performed in the reflector mode, averaging 50–100 individual laser shots.

**Determination of Equilibrium Constants for Dissociation ( $K_i$ ) of Complexes between Cystatin C Variants and Cathepsin B**—Methods used for active site titration and determination of equilibrium constants for dissociation ( $K_i$ ) of complexes between cystatin C and cysteine peptidases have been reviewed in detail (26). Briefly, the active concentrations of the different cystatin C variants, except L68Q cystatin C stab2, were determined by titration with papain and using benzoyl-DL-arginine 4-nitroanilide as the substrate. The papain used had previously been active site-titrated using L-3-carboxy-2,3-*trans*-epoxypropionyl-leucylamido(4-guanidino)butane. The assay buffer was 100 mM sodium phosphate, pH 6.5, containing 1 mM dithiothreitol and 2 mM EDTA to activate the enzyme. The absorbance of the cleaved 4-nitroanilide was measured at 405 nm in a Labsystems Multiskan Plus spectrophotometer.

Because of the low expression level of L68Q cystatin C stab2, titration of this protein was performed in a more dilute system than the one described above, using ~30 nM papain and the fluorogenic substrate Z-Phe-Arg-NHMec. This dilution does not influence the binding between the enzyme and its inhibitor because the dissociation constant of the papain-cystatin C complex is known to be in the femtomolar range (22). Two and a half  $\mu\text{l}$  of active site titrated papain solution was thus mixed with 5  $\mu\text{l}$  of assay buffer and incubated for 15 min at 37 °C. After addition of 2.5  $\mu\text{l}$  of a solution of L68Q cystatin C stab2 in different dilutions, the mixtures were incubated for 30 min at 37 °C. The mixture was then diluted 1:10 with 0.01% (w/v) Brij-35, and 2.5  $\mu\text{l}$  of the diluted sample was added to 62.5  $\mu\text{l}$  of 0.01% Brij-35, 25  $\mu\text{l}$  of 100 mM sodium phosphate buffer, pH 6.5, and 10  $\mu\text{l}$  of the substrate solution producing a final Z-Phe-Arg-NHMec concentration of 20  $\mu\text{M}$ . The samples were incubated at 37 °C for 10 min, after which the reaction was stopped by adding 100  $\mu\text{l}$  of 100 mM monochloroacetic acid, pH 4.3. Fluorescence was measured in a FLUOstar OPTIMA instrument (BMG Labtechnologies, Offenburg, Germany) at excitation and emission wavelengths of 390 and 460 nm, respectively.

A continuous rate assay (27) was used to measure the equilibrium constants for dissociation ( $K_i$ ) of complexes between cathepsin B and the different cystatin C variants. The substrate used was Z-Phe-Arg-NHMec (10  $\mu\text{M}$ ), and the assay buffer was 100 mM sodium phosphate, pH 6.0, containing 1 mM dithiothreitol and 2 mM EDTA. Steady-state velocities before ( $v_0$ ) and after ( $v_i$ ) addition of inhibitor (*I*) were measured, and the apparent  $K_i$  values were calculated as the slope from plots of  $[I]/(1 - v/v_0)$  versus  $v/v_0$  (28). A PerkinElmer LS-50 fluorimeter and excitation and emission wavelengths of 360 and 460 nm, respectively, were used for all cystatin C variants, except for L68Q cystatin C stab2. L68Q cystatin C stab2 was analyzed in the same way but at a final volume of 150  $\mu\text{l}$  instead of 3 ml and using a FLUOstar OPTIMA

fluorimeter with excitation and emission wavelengths of 390 and 460 nm, respectively.

**Dimerization Experiments**—A suitable *in vitro* system to promote dimerization of wt cystatin C was developed to allow investigations of the potential for dimer formation of wt cystatin C and ways to inhibit it. Guanidinium chloride was added to a solution of wt cystatin C at 0.5 mg/ml in PBS, to a final concentration of 0.5 M. The solution was then incubated at 37 °C for up to 25 days. The two stabilized variants of wt cystatin C (wt cystatin C stab1 and wt cystatin C stab2) were incubated at the same conditions. L68Q cystatin C dimerizes spontaneously in physiological buffers, and its dimerization rate at 0.2 mg/ml was therefore studied in PBS at 37 °C for up to 7 days. The dimerization rate of the stabilized L68Q cystatin C stab1 was studied at the same conditions. Because of low expression levels, L68Q cystatin C stab2 was tested at a lower concentration (~0.05 mg/ml). Dimers of both wt cystatin C and L68Q cystatin C display mobilities different from those of the monomeric proteins in agarose gel electrophoresis at pH 8.6 (4). Agarose gel electrophoresis was therefore used to follow the production of cystatin C dimers. Quantitative determinations were based upon densitometric scanning of agarose gel electropherograms using an Epson Expression 1680 Pro scanner and the “Quantity One” program from Bio-Rad. Several samples were also analyzed by gel chromatography on a calibrated Superdex HR75 column to verify the results obtained by scanning of agarose gel electropherograms.

Scanning of agarose gel electropherograms could also be used to follow the production of cystatin C dimers in incubation mixtures containing carboxymethylpapain or monoclonal antibodies against cystatin C, because the complexes formed between these substances and wt cystatin C or L68Q cystatin C differed in mobility from those of monomeric and dimeric wt and L68Q cystatin C. The production, properties, and isolation of the IgG2b( $\kappa$ ) murine antibody against cystatin C used in these experiments have been described previously (21). So have the production, properties, and isolation of the IgG2b( $\kappa$ ) murine antibody against protein HC used in control experiments (29). The concentration of anticystatin C antibody was determined by UV absorption spectroscopy at 280 nm using a molar extinction coefficient of  $\epsilon = 214,500 \text{ M}^{-1} \text{ cm}^{-1}$  ( $A_{280, 0.1\%} = 1.43$ ). Papain (lyophilized powder, crystallized) obtained from Sigma was further purified by affinity chromatography at 4 °C using a column of H-Gly-Gly-Tyr-Arg-Sepharose as described by Blumberg *et al.* (30) and used for the preparation of carboxymethylpapain. To 1 ml of a solution of papain (7 mg/ml) in 0.2 M sodium phosphate buffer, pH 6.0, containing 4 mM cysteine and 2 mM EDTA, was added 0.1 ml of a solution of 250 mM iodoacetamide in 0.5 M sodium phosphate buffer, pH 6.0. After 15 min in room temperature, the mixture was dialyzed against PBS. The concentration of carboxymethylpapain was determined by UV absorption spectroscopy at 280 nm using a molar extinction coefficient of  $\epsilon = 58,500 \text{ M}^{-1} \text{ cm}^{-1}$  ( $A_{280, 0.1\%} = 2.39$ ) (31).


**Amyloid Fibril Formation**—Wild type cystatin C, wt cystatin C stab1, and wt cystatin C stab2 were incubated at concentrations of 3 mg/ml in 10 mM glycine buffer, pH 2.0, containing 0.2% (w/v) sodium azide, at 48 °C under constant stirring using a magnetic spinbar. The appearance of amyloid fibrils in the incubation mixtures was repeatedly analyzed for 4 weeks by electron microscopy and by the thioflavin T fluorescence assay (32, 33).

**Electron Microscopy of Amyloid Fibrils**—Protein samples (5  $\mu\text{l}$ ) were applied on a glow-discharged carbon-coated copper grid (400-mesh). After 1 min of adsorption, excess liquid was removed using filter paper and the samples were dried. The samples were then negatively stained with 2% (w/v) aqueous uranyl acetate and examined with a Philips CM10 electron microscope (Philips, Eindhoven, The Netherlands), operating at an excitation voltage of 60 kV.

**Quantitative Estimation of Amyloid Fibrils**—The formation of amyloid fibrils was estimated by the thioflavin T fluorescence assay as described by LeVine (32, 33). Samples of wt cystatin C, wt cystatin C stab1, and wt cystatin C stab2 (3 mg/ml) were diluted with 50 mM glycine-sodium hydroxide buffer, pH 8.5, containing 100  $\mu\text{M}$  thioflavin T to final protein concentrations of 7.5  $\mu\text{M}$  (calculated for the monomeric species). Measurements were carried out in polystyrene 96-well microtiter plates (Black Cliniplates, Thermo Labsystems, Helsinki, Finland) pretreated with Sigmacote (Sigma). The fluorescence was recorded using a FLUOstar OPTIMA fluorimeter at excitation and emission wavelengths of 450 and 490 nm, respectively.

## RESULTS


The conformational flexibility of monomeric wt and L68Q cystatin C allows these molecules to form dimers and possibly



**FIG. 1. A view of one half of the three-dimensional domain-swapped dimer of wt cystatin C, illustrating the positions selected in the present work for mutation to cysteine residues.** The mutations L47C/G69C were designed to introduce a new disulfide bond linking the strands  $\beta 2$  and  $\beta 3$  of the  $\beta$ -sheet. The mutations F29C/M110C were designed to introduce a connection between the  $\alpha$ -helix and strand  $\beta 5$ . In the domain-swapped dimer of wt cystatin C, strand  $\beta 2$  and the  $\alpha$ -helix are contributed by one of the monomers and strands  $\beta 3$  and  $\beta 5$  by the other. The figure, prepared using MOLMOL (16), is based on the coordinates deposited in the Protein Data Bank (accession code 1G96). The coordinates of the new cysteine residues (shown as ball-and-stick models) were obtained by mutating the coordinates of the original residues. The conformation of the side chains of the mutated cysteine residues could be easily adjusted manually in the molecular graphics program O (17) to achieve S-S distances in the paired cysteine residues of approximately 2–3 Å, without compromising stereochemistry. This is emphasized in the figure by the covalent disulfide bonds.

amyloid fibrils by domain swapping. To investigate whether suppression of this flexibility would also suppress the ability of the molecules to form dimers and fibrils, an attempt was made to produce two variants of each protein stabilized by an extra disulfide bridge for each variant. It was considered important to insert the new disulfide bridges in a way that would leave the general fold of cystatin C as intact as possible, preserving, for example, the capacity of the proteins to inhibit cysteine proteases. This was done by strategic insertion of new disulfide bridges aiming at anchoring the domain swapping subunits to the backbone of the cystatin C molecules without disruption of the general cystatin fold. In efforts to create the first type of stabilized monomeric wt and L68Q cystatin C molecules (called stab1), the mutations were selected to introduce a disulfide bridge between the  $\beta 2$ - and  $\beta 3$ -strands, which separate when dimeric cystatin C is formed (Fig. 1) (7). To create the second type of stabilized monomeric wt and L68Q cystatin C molecules (called stab2), the mutations were selected to introduce a disulfide bridge between the  $\alpha$ -helix and the  $\beta 5$ -strand, which also separate during the process of three-dimensional domain swapping of cystatin C (7).

**Expression and Purification of the Stabilized Cystatin C Variants**—An expression vector carrying the gene for wt cystatin C (14) was subjected to oligonucleotide-directed mutagenesis to create vectors with genes encoding L47C/G69C and F29C/M110C cystatin C as well as L47C/L68Q/G69C and F29C/L68Q/M110C cystatin C. After sequencing, the expression vectors were introduced into *E. coli* MC1061. It was thus possible to express two potentially stabilized variants of wt cystatin C (wt cystatin C stab1 and wt cystatin C stab2), and two potentially stabilized variants of L68Q cystatin C (L68Q cystatin C stab1 and L68Q cystatin C stab2). The expression levels of the cystatin C variants differed considerably, requiring different isolation procedures. Wild type cystatin C and its two variants were isolated by a two-step procedure consisting




**FIG. 2. Agarose gel electrophoresis of wt cystatin C, wt cystatin C stab1, and wt cystatin C stab2.** Solutions of wt cystatin C, wt cystatin C stab1, and wt cystatin C stab2 in phosphate-buffered saline, pH 7.4, containing 0.5 M guanidinium chloride were incubated at 37 °C for 7 days and analyzed by agarose gel electrophoresis at pH 8.6. The electrophoretic mobilities of monomeric and dimeric cystatin C are indicated by arrows. The anode and the point of application are marked by a plus sign and an arrow, respectively. Human blood plasma is used as a reference.

of anion exchange chromatography at pH 9.0, followed by gel chromatography (14, 20). Both wt cystatin C stab1 and wt cystatin C stab2 eluted from a calibrated Superdex HR 75 column at the position corresponding to monomeric wt cystatin C. The expression levels for the two purified protein variants were comparable with that of wt cystatin C with a yield of 3–15 mg of protein/liter of culture.

The expression levels of L68Q cystatin C, L68Q cystatin C stab1, and L68Q cystatin C stab2 were considerably lower (0.05–0.5 mg of protein/liter of culture) and these proteins could not be isolated using ion exchange chromatography. Concentrated periplasmic extracts of L68Q cystatin C and its two variants were therefore subjected to immunosorption as previously described (4), using a monoclonal anticystatin C antibody coupled to Sepharose beads. The proteins were eluted with a buffer containing 6 M guanidinium chloride. After concentration of the eluate, gel filtration on a Superdex HR 75 column in PBS at room temperature was used as the final purification step. The elution positions of L68Q cystatin C and its stabilized variants coincided with that of monomeric wt cystatin C.

**Physicochemical Characterization of the Cystatin C Variants**—The wt and L68Q cystatin C variants were analyzed by agarose gel and SDS-PAGE electrophoresis. Agarose gel electrophoresis demonstrated that the charges of all four variants at pH 8.6 were identical and agreed with those of wt and L68Q cystatin C (Figs. 2 and 3). SDS-PAGE electrophoresis showed that the apparent sizes of all the variants also were identical and in accordance with those of wt and L68Q cystatin C.

To verify that the positions of the disulfide bridges in wt cystatin C, wt cystatin C stab1, wt cystatin C stab2, and L68Q cystatin C were as expected, unreduced samples were incubated with trypsin and the generated peptides were analyzed by mass spectrometry. The digestions were made in the presence of *N*-ethylmaleimide (an alkylating agent) to avoid reshuffling of the disulfide bridges upon digestion. No alkylation of cysteines was observed, indicating that the disulfides were kept intact during the digestion procedure. Fragments corresponding to the anticipated disulfide bridges between residues 73 and 83, 97 and 117, 47 and 69, and between residues 29 and 110 could be identified, whereas no fragments corresponding to other disulfide bridges were found (Table II). Digestion of wt cystatin C stab2 also produced a fragment comprising three



**FIG. 3. Agarose gel electrophoresis of L68Q cystatin C, L68Q cystatin C stab1, and L68Q cystatin C stab2.** Solutions of L68Q cystatin C, L68Q cystatin C stab1, and L68Q cystatin C stab2 in phosphate-buffered saline, pH 7.4, were incubated at 37 °C for 2 h and analyzed by agarose gel electrophoresis at pH 8.6. The electrophoretic mobilities of monomeric and dimeric cystatin C are indicated by arrows. The anode and the point of application are marked by a plus sign and an arrow, respectively. Human blood plasma is used as a reference.

oligopeptides with two disulfide bridges between the oligopeptides, compatible with the expected arrangement of the disulfide bonds in this wt cystatin C variant. A few peptides with intact trypsin cleavage sites were also identified, but all were compatible with the expected arrangement of the disulfide bridges.

To further examine whether or not the introduced disulfide bridges had significantly altered the tertiary structure of the cystatin C variants, the cysteine protease-inhibiting capacities of the proteins were investigated. This was done by determination of the equilibrium constants for dissociation ( $K_i$ ) of complexes between cathepsin B and the different cystatin C variants using a continuous-rate enzyme analysis. It was observed that all four stabilized cystatin C variants as well as wt and L68Q cystatin C displayed virtually identical equilibrium constants for inhibition of cathepsin B (Table III).

**Dimerization of the Cystatin C Variants**—The crystal structure of dimeric wt cystatin C demonstrates that the dimer is formed via three-dimensional swapping of domains between the two participating wt cystatin C monomers (7). To compare the domain swapping potentials of the stabilized cystatin C variants with those of the parent molecules, wt and L68Q cystatin C, the capability of all the proteins to form dimers was investigated.

Although wt cystatin C crystallizes in dimeric form from concentrated solutions, it is known to be quite stable as a monomer under physiological conditions (4). It was, therefore, necessary to use mildly denaturing conditions when its potential for dimer formation was studied. We have established an *in vitro* system for wt cystatin C in PBS with 0.5 M guanidinium chloride at 37 °C as a suitable system to facilitate dimerization. Aliquots were removed at timed intervals and subjected to agarose gel electrophoresis to study the formation of dimers, which have higher anodal electrophoretic mobility than the monomers (Fig. 2). Densitometric scanning of the electropherograms was used to determine the ratio between the monomers and dimers. Furthermore, to verify the results, several samples were studied by gel chromatography. When samples of wt cystatin C were incubated at 37 °C, significant amounts of dimers were seen within 3 days, whereas wt cystatin C stab1 and wt cystatin C stab2 did not produce any dimers at all when incubated at identical conditions (Fig. 2). Indeed, no dimers of the stabilized wt cystatin C variants could be observed even

after a prolonged incubation period of 28 days (Fig. 4). No difference in their potential for dimer formation could be found between the two stabilized variants.

In contrast to wt cystatin C, L68Q cystatin C dimerizes spontaneously within a short period of time in physiological buffers (4). Freshly isolated L68Q cystatin C was therefore incubated in PBS at 37 °C, and a significant amount of dimers could already be observed after 2 h (Fig. 3). When the two stabilized variants of L68Q cystatin C (L68Q cystatin C stab1 and L68Q cystatin C stab2) were incubated at the same conditions, no dimers were produced even after incubation periods of up to 7 days (Fig. 4). L68Q cystatin C stab1 and its L68Q cystatin C control were incubated at a concentration of 0.2 mg/ml. Because of the very low expression level of L68Q cystatin C stab2, this protein had to be tested in a lower concentration (0.05 mg/ml). L68Q cystatin C stab2 and its L68Q cystatin C control at the same concentration were therefore immunoprecipitated prior to staining for protein (Fig. 3).

**In Vitro Production of Amyloid Fibrils from wt Cystatin C and Its Stabilized Variants**—To investigate whether amyloid fibril production from wt cystatin C could be suppressed by stabilizing the monomeric form, an *in vitro* system was developed for production of fibrils from wt cystatin C. Several conditions for fibril production were examined, including different buffers (pH 2.0–7.8), different temperatures (37, 48, or 65 °C), different protein concentrations, and incubation with or without stirring. Fibrils of wt cystatin C were found to be produced in solutions of low pH, and the production was accelerated by high temperature and stirring. We selected a cystatin C concentration of 3 mg/ml, incubation in 10 mM glycine buffer, pH 2.0, and continuous magnetic stirring at 48 °C for fibril production in this study. Identical conditions were used to investigate fibril formation of wt cystatin C stab1 and wt cystatin C stab2. The fibrils showed tinctorial properties characteristic of amyloid when stained with both Congo red and thioflavin T, and the spectral alterations on binding of both dyes were typical for amyloid fibrils. Electron micrographs of the fibrils showed long, nonbranching, twisted, wirelike structures approximately 10 nm wide (Fig. 5). No fibrils could be detected in the solutions at the start of the incubation period. After approximately 1 day, a low amount of fibrils could be observed in the solution of wt cystatin C but not in the solutions of its two stabilized variants. After 7 days of incubation, a substantial amount of fibrils could be observed in the solution of wt cystatin C, whereas only low amounts of fibrils were present in the solutions of wt cystatin C stab1 and wt cystatin C stab2. A thioflavin T assay was used to quantitatively follow the production of fibrils from the three proteins. As can be seen in Fig. 6, wt cystatin C had produced a considerable amount of fibrils after 7 days of incubation and the amount of fibrils increased continuously for at least 3 more weeks, although at a lower rate than during the first week. In contrast, after incubation periods of more than 7 days, the amounts of fibrils produced from wt cystatin C stab1 or wt cystatin C stab2 corresponded to only approximately 20% of that produced from wt cystatin C (Fig. 6). The low expression levels of L68Q cystatin C and its variants did not allow studies of their capacities to form fibrils.

**Suppression of Dimerization of wt Cystatin C and L68Q Cystatin C by Monoclonal Antibodies and Carboxymethylpapain**—Although additional disulfide bridges introduced into wt and L68Q cystatin C seem to be able to suppress the capacity of these proteins to dimerize and produce amyloid fibrils, it is interesting from *inter alia* a therapeutic point of view to investigate whether exogenous agents might also display similar effects. We therefore investigated whether a monoclonal antibody raised against wt cystatin C (21) would be able to inhibit

TABLE II  
Tryptic digestion of wt cystatin C, wt cystatin C stab1, wt cystatin C stab2, and L68Q cystatin C analyzed by matrix-assisted laser desorption time-of-flight mass spectrometry

Cysteine residues participating in disulfide bridges are underlined. The number of intact trypsin cleavage sites in the peptides is shown in parentheses. The peptide specific for L68Q cystatin C is shown in italics.

Cystatin C variant	Peptide sequences	Residues	Mass obtained	Mass calculated
wt cystatin C	TTCTK + TQPNLDNCPFHDPHLK	71–75 (0) 76–92 (0)	2554.3	2554.2
wt cystatin C	TTCTKTQPNLDNCPFHDPHLK	71–92 (1)	2536.3	2536.2
wt cystatin C	AFCSFQIYAVPWQGTMTLSK + STCQDA	95–114 (0) 115–120 (0)	2899.4	2899.3
wt cystatin C	AFCSFQIYAVPWQGTMTLSKSTCQDA	95–120 (1)	2881.4	2881.3
wt cystatin C stab1	ACQVVR + QIVAGVNYFLDVELCR	46–51 (0) 55–70 (0)	2511.2	2511.3
wt cystatin C stab1	TTCTK + TQPNLDNCPFHDPHLK	71–75 (0) 76–92 (0)	2554.3	2554.2
wt cystatin C stab1	AFCSFQIYAVPWQGTMTLSK + STCQDA	95–114 (0) 115–120 (0)	2899.3	2899.3
wt cystatin C stab2	TTCTK + TQPNLDNCPFHDPHLK	71–75 (0) 76–92 (0)	2554.3	2554.2
wt cystatin C stab2	AFCSFQIYAVPWQGTCTLSK + STCQDA + ALDCAVGEYNK	95–114 (0) 115–120 (0) 26–36 (0)	4050.8	4050.8
L68Q cystatin C	TTCTK + TQPNLDNCPFHDPHLK	71–75 (0) 76–92 (0)	2554.3	2554.2
L68Q cystatin C	AFCSFQIYAVPWQGTMTLSK + STCQDA	95–114 (0) 115–120 (0)	2899.4	2899.3
<i>L68Q cystatin C</i>	<i>QIVAGVNYFLDVEQGR</i>	<i>55–70 (0)</i>	<i>1807.9</i>	<i>1807.9</i>

TABLE III  
Equilibrium constants for dissociation ( $K_i$ ) of the complexes between cathepsin B and the different cystatin C variants

The standard deviation (S.D.) and number of measurements ( $n$ ) used to calculate the mean  $K_i$  values given are indicated.

Cystatin C variant	$K_i$	S.D.	$n$
	<i>nm</i>	<i>nm</i>	
wt cystatin C	0.37	±0.068	6
wt cystatin C stab1	0.23	±0.022	5
wt cystatin C stab2	0.35	±0.012	5
L68Q cystatin C	0.40 <sup>a</sup>		
L68Q cystatin C stab1	0.36	±0.049	5
L68Q cystatin C stab2	0.43	±0.032	6

<sup>a</sup> The  $K_i$  of L68Q cystatin C has previously been determined by Abrahamson and Grubb (4).

dimerization of wt and L68Q cystatin C. The incubation systems described previously were used for the induction of dimerization of wt and L68Q cystatin C (PBS with 0.5 M guanidinium chloride at 37 °C and PBS at 37 °C, respectively). The monoclonal antibody was added in varying amounts corresponding to antibody:cystatin C molar ratios of 1:500 to 1:5 and the incubation periods studied were 1, 4, and 7 days for wt cystatin C, and 0.5, 2, and 24 h for L68Q cystatin C. The dimer fractions of wt and L68Q cystatin C were estimated from agarose gel electrophoresis of the incubation mixtures. In a control experiment, the IgG2b( $\kappa$ ) murine antibody against cystatin C was replaced with an IgG2b( $\kappa$ ) murine monoclonal antibody against an unrelated antigen (protein HC). Suppression of the dimer formation of wt cystatin C was obtained at all incubation periods, and the suppression increased with the antibody:cystatin C molar ratio (Fig. 7A). Surprisingly, even at low antibody:cystatin C molar ratios, the formation of dimers was significantly suppressed. After 4 days of incubation of wt cystatin C at an antibody:cystatin C molar ratio of 1:50, a suppression of the dimer formation of approximately 65% was obtained (Fig. 7A). Similar results were obtained for L68Q cystatin C. After 30 min of incubation of L68Q cystatin C at an antibody:cystatin C molar ratio of 1:50, a suppression of the dimer formation of approximately 50% was obtained (Fig. 7A). An antibody:cystatin C molar ratio of 1:5 totally suppressed the formation of



dimers of wt and L68Q cystatin C even after the longest incubation periods tested (7 days for wt cystatin C and 24 h for L68Q cystatin C). The control antibody did not suppress the formation of dimers.

The cysteine protease papain and its active site-alkylated inert derivative, carboxymethylpapain, bind strongly to the inhibitory centers of monomeric wt and L68Q cystatin C. We, therefore, tested whether carboxymethylpapain was able to suppress the formation of dimers of wt cystatin C and L68Q cystatin C. The systems described above for induction of wt and L68Q cystatin C dimerization were used. Carboxymethylpapain was added in varying amounts corresponding to carboxymethylpapain:cystatin C molar ratios of 1:20 to 1:2, and the incubation periods studied were 1, 4, and 7 days for wt cystatin C and 0.5, 2, and 24 h for L68Q cystatin C. The dimer and monomer fractions of wt cystatin C and L68Q cystatin C were estimated from agarose gel electrophoresis of the incubation mixtures. Suppression of dimer formation was obtained at all incubation periods, and the suppression increased with the carboxymethylpapain:cystatin C molar ratio (Fig. 7B). Even carboxymethylpapain:cystatin C molar ratios considerably below 1 significantly suppressed the formation of dimers. After 4 days of incubation at a carboxymethylpapain:cystatin C molar ratio of 1:6, a suppression of the dimer formation of wt cystatin C of approximately 40% was obtained (Fig. 7B). After 30 min of incubation at a carboxymethylpapain:cystatin C molar ratio of 1:6, a suppression of the dimer formation of L68Q cystatin C of approximately 40% was also obtained (Fig. 7B).

#### DISCUSSION


At least 20 unrelated proteins have been observed to form amyloid fibrils associated with human disease, *e.g.* Alzheimer's disease, familial amyloid polyneuropathy, reactive amyloidosis, myeloma-associated amyloidosis, and the prionoses. Knowledge of the molecular pathophysiological mechanism causing the transition of physiologically normal and soluble proteins and peptides to toxic oligomers and insoluble fibrils is crucial in efforts to develop treatment modalities for this group of common diseases (9, 34–38). Recent elucidation of the crystal structure of certain amyloidogenic proteins, like the human prion protein and cystatin C, has shown that these proteins

**FIG. 4. Dimerization rate of wt cystatin C, wt cystatin C stab1, wt cystatin C stab2, L68Q cystatin C, L68Q cystatin C stab1, and L68Q cystatin C stab2.** Solutions of wt cystatin C (●), wt cystatin C stab1 (■), and wt cystatin C stab2 (■) were incubated in phosphate-buffered saline, pH 7.4, containing 0.5 M guanidinium chloride at 37 °C for up to 28 days. Solutions of L68Q cystatin C (○), L68Q cystatin C stab1 (■), and L68Q cystatin C stab2 (■) were incubated in phosphate-buffered saline, pH 7.4, at 37 °C for up to 7 days. The *inset* shows the early phase of dimerization of L68Q cystatin C. No dimerization of the four cystatin C variants stabilized by disulfide bridges could be observed.



**FIG. 5. Electron microscopy of fibrils formed from wt cystatin C.** *A* and *B* show, at different magnifications, fibrils produced from a solution of wt cystatin C (3 mg/ml) in 10 mM glycine buffer, pH 2.0, stirred at 48 °C for 7 days. Bars of 1 μm or 100 nm, respectively, are used as indicators of size.

form dimers by the process of three-dimensional domain swapping (7, 10). The concept of three-dimensional domain swapping, as defined by Eisenberg, refers to the situation where an element of the tertiary structure of a protein has been replaced with an identical piece from another protein molecule (8). In addition to being a mechanism for dimerization of proteins, propagated three-dimensional domain swapping has also been




**FIG. 6. Time course of amyloid fibril formation of wt cystatin C, wt cystatin C stab1, and wt cystatin C stab2 determined by a thioflavin T fluorescence assay.** Fibrils produced from solutions of wt cystatin C (●), wt cystatin C stab1 (□), and wt cystatin C stab2 (■) (3 mg/ml) in 10 mM glycine buffer, pH 2.0, stirred at 48 °C for various periods of time were quantified by the thioflavin T (*ThT*) fluorescence assay.

suggested as a mechanism for fibril formation of amyloidogenic proteins (7, 9–11, 39–42). This hypothesis has found confirmation in the recent experiments of Lee and Eisenberg (11), who not only provided evidence that the three-dimensional domain swapping reported for the prion protein (10) is indeed involved in amyloid fibril formation, but also demonstrated, for the first time, that such fibrils obtained from recombinant material carry a “seeding effect,” thus resembling the replication process of an infectious agent.

The general fold of monomeric proteins of the cystatin superfamily has been defined by the crystal structure of chicken cystatin and consists of a long  $\alpha$ -helix running across a large  $\beta$ -sheet containing five antiparallel  $\beta$ -strands ( $\beta$ 1– $\beta$ 5) (12). The crystal structure of dimeric wt cystatin C has revealed that the structural fragment that undergoes swapping consists of the  $\alpha$ -helix and the flanking  $\beta$ 1- and  $\beta$ 2-strands (7). If this type of domain swapping indeed is the pathophysiological mechanism of dimerization and fibrillization of wt cystatin C and of the naturally occurring even more fibrillogenic variant, L68Q cystatin C, it should be possible to inhibit these processes by





**FIG. 7. Suppression of dimer formation of wt cystatin C and L68Q cystatin C by monoclonal antibodies (A) and carboxymethylpapain (B).** Wild type cystatin C (●) (0.5 mg/ml) was incubated at 37 °C for 4 days in phosphate-buffered saline, pH 7.4, containing 0.5 M guanidinium chloride, with different amounts of a monoclonal antibody against cystatin C (A) or different amounts of carboxymethylpapain (B). L68Q cystatin C (○) (0.2 mg/ml) was incubated at 37 °C for 30 min in phosphate-buffered saline, pH 7.4, with different amounts of a monoclonal antibody against cystatin C (A) or different amounts of carboxymethylpapain (B). The degree of suppression of dimer formation was calculated from the amounts of dimers formed without additions of monoclonal antibodies or carboxymethylpapain to the solutions of wt cystatin C or L68Q cystatin C.

preventing domain swapping. In the present study we have tried to produce two variants of both wt cystatin C and L68Q cystatin C that are resistant to the identified type of domain swapping and to investigate whether these stabilized cystatin C variants are less prone to form dimers and amyloid fibrils. Using the crystallographic three-dimensional structure of dimeric wt cystatin C (Protein Data Bank accession code 1G96), we looked for amino acid residues at the closed interface of the dimer, which are proximal in space and which, when substituted by cysteine residues, could form intramolecular disulfide bonds. This strategy was based on the observation that the closed interface of a monomeric protein is recreated in the domain-swapped oligomer with high fidelity (43). Two topological areas were selected (Fig. 1 and Table I). In the first variant of wt and L68Q cystatin C, the two mutations L47C and G69C were designed for creating a link between the  $\beta$ 2- and  $\beta$ 3-strands of the  $\beta$ -sheet (Fig. 1). In the second variant of wt and

L68Q cystatin C, the two mutations F29C and M110C were designed for creating a link between the  $\alpha$ -helix and the  $\beta$ 5-strand (Fig. 1). These positions of the putative new disulfide bonds, although leaving the general fold and the biological function of the proteins unchanged, have the capacity to link together the two parts of monomeric cystatin C, which undergo swapping between the two molecules on dimerization (7). In both cases, the new disulfide bond should stabilize the monomer and prevent its unfolding, which is a prerequisite of three-dimensional domain swapping. It is true that, if the domain swapping act did take place, then the extra disulfide links would stabilize the domain-exchanged dimer. The idea is, however, that (because the starting material is monomeric) the additional disulfide bridges will make the monomers sufficiently stable so that no domain swapping will be possible. This aspect of the disulfide links suggests additional, attractive experiments. Specifically, it should be possible to influence the stabilizing effect of the disulfide bonds by careful control of the redox environment of the protein. In this respect the engineered cysteine mutants of cystatin C would resemble the prion protein with its intramolecular disulfide bond that must be broken and re-formed when domain swapping dimerization takes place (10) and which can be used for denaturation/redox control of dimerization and fibril formation (11). Such experiments are, however, not the subject of the present paper and will be conducted in the future.

All four stabilized cystatin C variants displayed the same electrophoretic mobility in agarose gel and dodecyl sulfate polyacrylamide gel electrophoresis as the parent wt and L68Q cystatin C molecules and showed identical elution volumes in gel chromatography. All variants inhibited papain efficiently, and determinations of their equilibrium constants for dissociation of their complexes with the cysteine protease cathepsin B displayed that these constants were identical with those of the parent molecules wt and L68Q cystatin C. Direct determination by tryptic digestion followed by mass spectrometry of the location of the disulfide bridges in wt cystatin C, in its two stabilized variants, and in L68Q cystatin C demonstrated that the new disulfide bridges have cross-linked the intended parts of the molecules correctly. Although the low expression levels for the L68Q cystatin C variants did not allow a similar study of their disulfide bridges, the combined data clearly indicate that all variants produced are monomeric and have the same biological activity as the parent molecules, despite the introduction of the new disulfide bridges. In conclusion, the design and execution of the mutation experiments have produced the expected results, *i.e.* introduced the desired new disulfide bonds in the monomeric structure of wt and L68Q cystatin C with retention of the native fold.

The capacity of the two variants of wt and L68Q cystatin C to form dimers was then investigated. Because L68Q cystatin C dimerizes spontaneously in physiological buffers, even at room temperature (4), and can be found in patients (5), the capacity of the two L68Q variants to dimerize was investigated using a physiological buffer and the temperature of 37 °C. Whereas a major part of L68Q cystatin C forms dimers at these conditions within 30 min, the two L68Q variants did not form any detectable amounts of dimers even after incubation periods of 7 days. This strongly indicates that the introduction of the disulfide bridges in the L68Q variants did stabilize the molecules in a way that prevents dimerization. In contrast to L68Q cystatin C, wt cystatin C forms dimers very slowly in physiological buffers (4, 6). Therefore, to be able to investigate the stabilizing effect of the disulfide bridges introduced in the variants of wt cystatin C, a mildly denaturing system at pH 7.4 and 37 °C containing 0.5 M guanidinium chloride was used. In this system, approxi-

mately 50% of wt cystatin C formed dimers within 3 days, whereas the two stabilized variants of wt cystatin C did not form any detectable amounts of dimers even after prolonged incubation periods of 28 days. These results also indicate that the new disulfide bridges introduced in the wt cystatin C variants do prevent dimerization. The mechanisms for stabilization of the variants of both wt and L68Q cystatin C are probably identical, with the disulfide bridges preventing the partial unfolding that is a prerequisite of the domain swapping occurring during the formation of cystatin C dimers (7). Furthermore, both locations of the disulfide bridge, between the  $\beta$ 2- and  $\beta$ 3-strands or between the  $\alpha$ -helix and the  $\beta$ 5-strand, seem to be equally efficient for the stabilization of wt and L68Q cystatin C. The strategy to introduce extra disulfide bonds to increase the stability of engineered proteins has been used with success previously, e.g. for lysozyme and human RNase I (44, 45), but to the best of our knowledge the presently described use of new disulfide bridges to prevent domain swapping has not been reported before.

It has been suggested by several authors that three-dimensional domain swapping is involved not only in the formation of protein dimers but also in the formation of amyloid fibrils (7, 9–11, 39–42). Originally a mere speculation, this hypothesis has recently become a very real possibility, particularly in the light of the discoveries involving prion proteins and cystatin C (7, 9–11). It was therefore of interest to investigate whether prevention of domain swapping would have an inhibitory effect not only on dimer formation but also on the formation of amyloid fibrils. Although conditions producing fibrils of cystatin B have been described (46), we were not able to produce cystatin C amyloid fibrils using these conditions. We, therefore, tested several different conditions and were finally able to establish a system for the production of fibrils of wt cystatin C. These fibrils displayed the tinctorial properties described for amyloid fibrils when stained with Congo red or thioflavin T and showed the typical fibrous appearance when studied by electron microscopy. This system was used to compare the fibril forming capacity of wt cystatin C and its two variants stabilized by the engineered disulfide bridges. A quantitative method, based upon binding of thioflavin T, was used to follow the development of fibrils from the three cystatin C variants. Considerable amounts of fibrils were formed from wt cystatin C after incubation periods of 7 days or more, whereas the two stabilized forms of wt cystatin C only formed small amounts of fibrils, corresponding to no more than 20% of the fibrils formed from wt cystatin C. Prevention of domain swapping, therefore, seems to be able to substantially reduce the formation of amyloid fibrils, at least in the system tested.

It is not clear why preventing domain swapping completely inhibits dimerization of cystatin C, whereas it only inhibits approximately 80% of the ability of cystatin C to form amyloid fibrils. However, it should be remembered that the systems used to induce dimerization of the parent cystatin C molecules and the system used to form amyloid fibrils are very different. Indeed, the system used for production of amyloid fibrils involved strongly acidic conditions, and it has been suggested by Dobson that most, if not all, proteins will produce fibrils if sufficiently strong denaturing incubation conditions are used (47). It is thus possible that, in the harsh conditions used for induction of fibril formation, even the stabilized protein variants became unstable, i.e. partially unfolded, and entered on the aggregation pathway. Of course, there is still another possibility that the formation of fibrils could proceed in several ways. In such a scenario, prevention of cystatin C domain swapping in the presently used system for production of fibrils would completely abolish one important way of fibril formation

but not necessarily other fibril forming pathways.

Although the data presented here indicate that prevention of domain swapping of cystatin C also will prevent, or substantially decrease, dimer and fibril formation, it should be remembered that the *in vitro* conditions used drastically differ from the tissue milieu in which amyloid fibrils are formed in amyloid disorders. It is also still an open question whether or not it is the fibrils *per se* or other smaller oligomers that contribute to the pathogenic symptoms of amyloid disorders (38, 48). It has been observed that, when different proteins are induced to form fibrils *in vitro*, oligomers that form early in the process are toxic to cells whereas the fibrils themselves are nontoxic (49, 50). It has also been stated that the pathophysiological roles of oligomers and fibrils must be clarified before efficient treatment modalities for amyloid disorders can be obtained (48). Although this might be true, the underlying mechanism for the formation of potentially toxic oligomeric precursors is presumably the same as that for fibril formation, which means that substances known to inhibit fibril formation also might inhibit the formation of their oligomeric precursors.

Although the production of cystatin C variants stabilized against domain swapping is very useful in demonstrating that prevention of domain swapping has the capacity to inhibit formation of dimers and amyloid fibrils, it is obvious that, if treatment strategies based upon prevention of domain swapping are to be developed, exogenous agents stabilizing the monomeric form of cystatin C must be sought. We therefore studied whether a monoclonal antibody raised against wt cystatin C could inhibit the cystatin C dimerization process and found that the antibody could suppress the dimerization of both wt and L68Q cystatin C. This observation might be related to the discovery that antibodies to surface epitopes of PrP<sup>C</sup> can inhibit the generation of the amyloidogenic molecular species PrP<sup>Sc</sup> and thereby interfere with prion biogenesis (51). It has been speculated that the effect of the antiprion antibodies was the result either of their stabilization of PrP<sup>C</sup>, preventing its refolding into PrP<sup>Sc</sup>, or of their inhibition of the interaction between PrP<sup>C</sup> and PrP<sup>Sc</sup> (51). The molar ratio between the antiprion antibodies and the prion proteins was not investigated, but the simple system used in the present investigation allowed the calculation of the effective antibody:cystatin C molar ratio. Surprisingly, this was found to be very low, and a molar ratio of 1:50 inhibited more than 50% of the dimerization of both wt and L68Q cystatin C in the systems tested. The reason that almost catalytic amounts of antibodies were effective in inhibiting dimerization is encouraging from a therapeutic point of view, but the molecular mechanism is not apparent. However, it has previously been observed that low molar amounts of a protein might inhibit fibrillogenesis of another protein. Specifically, gelsolin has been shown to inhibit *in vitro* fibrillization of synthetic A $\beta$ 1–40 and A $\beta$ 1–42 at a gelsolin to A $\beta$  molar ratio of 1:40 (52). It has also been described that IgG2b antibodies against the N-terminal A $\beta$ 4–10 epitope have the capacity to promote A $\beta$  fibril dissolution *in vitro* at antibody:A $\beta$  ratios of 1:20–1:50 (53). It is conceivable that the effect of low molar amounts of the anticystatin C antibody might be caused by the preferential reaction of the antibody with those partially unfolded cystatin C molecular species that are directly involved in the dimer producing domain swapping process. Another mechanism might be that the antibody preferentially reacts with dimeric cystatin C and monomerizes it in the process. Further investigations are obviously required to elucidate the mechanism through which catalytic amounts of anticystatin C antibodies inhibit the formation of dimeric cystatin C.

It is also noteworthy that carboxymethylpapain, an active

site-alkylated inert derivative of the cysteine protease papain, can inhibit the dimerization of wt and L68Q cystatin C at low molar ratios of carboxymethylpapain to cystatin C. It is known that papain and carboxymethylpapain strongly bind to the inhibitory centers of monomeric wt and L68Q cystatin C (4, 54). Dimeric cystatin C, in which the domain swapping rearrangement has totally disrupted the binding centers, does not bind to papain or carboxymethylpapain (4). Therefore, the molecular mechanism explaining the efficiency of low molar amounts of carboxymethylpapain in inhibiting dimerization of cystatin C hardly involves any interaction between cystatin C dimers and carboxymethylpapain.

The dimer-suppressing capacity of monoclonal anticystatin C antibodies and carboxymethylpapain indicates the feasibility of engineering low molecular mass compounds that might stabilize the native, monomeric form of wt and L68Q cystatin C to inhibit domain swapping, dimerization, and possibly pathogenic formation of oligomers and fibrils. Baures *et al.* (55) have previously successfully used this strategy to stabilize the native form of transthyretin with low molecular mass ligands, thereby preventing partial unfolding and amyloid fibril formation *in vitro*. In addition, it has been observed that the cyclic peptide Aplidine inhibits aggregation of the prion peptide PrP 106–126 into  $\beta$ -sheet-containing fibrils by strongly binding to the monomeric species (56). It might thus be possible to construct low molecular mass cystatin C binding molecules targeting, *e.g.*, the monoclonal antibody-binding site or the protease-binding site of cystatin C, thereby stabilizing its physiological form.

**Acknowledgment**—Some of the calculations for this work were performed at the Poznan Metropolitan Supercomputing and Networking Center.

## REFERENCES

- Grubb, A. O. (2000) *Adv. Clin. Chem.* **35**, 63–99
- Olafsson, I., and Grubb, A. (2000) *Amyloid* **7**, 70–79
- Yamada, M. (2000) *Neuropathology* **20**, 8–22
- Abrahamson, M., and Grubb, A. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91**, 1416–1420
- Bjarnadottir, M., Nilsson, C., Lindstrom, V., Westman, A., Davidsson, P., Thormodsson, F., Blondal, H., Gudmundsson, G., and Grubb, A. (2001) *Amyloid* **8**, 1–10
- Ekiel, I., and Abrahamson, M. (1996) *J. Biol. Chem.* **271**, 1314–1321
- Janowski, R., Kozak, M., Jankowska, E., Grzonka, Z., Grubb, A., Abrahamson, M., and Jaskolski, M. (2001) *Nat. Struct. Biol.* **8**, 316–320
- Bennett, M. J., Choe, S., and Eisenberg, D. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91**, 3127–3131
- Jaskolski, M. (2001) *Acta Biochim. Pol.* **48**, 807–827
- Knaus, K. J., Morillas, M., Swietnicki, W., Malone, M., Surewicz, W. K., and Yee, V. C. (2001) *Nat. Struct. Biol.* **8**, 770–774
- Lee, S., and Eisenberg, D. (2003) *Nat. Struct. Biol.* **10**, 725–730
- Bode, W., Engh, R., Musil, D., Thiele, U., Huber, R., Karshikov, A., Brzin, J., Kos, J., and Turk, V. (1988) *EMBO J.* **7**, 2593–2599
- Gerhartz, B., Ekiel, I., and Abrahamson, M. (1998) *Biochemistry* **37**, 17309–17317
- Abrahamson, M., Dalboge, H., Olafsson, I., Carlsen, S., and Grubb, A. (1988) *FEBS Lett.* **236**, 14–18
- Dalboge, H., Jensen, E. B., Tottrup, H., Grubb, A., Abrahamson, M., Olafsson, I., and Carlsen, S. (1989) *Gene (Amst.)* **79**, 325–332
- Koradi, R., Billeter, M., and Wuthrich, K. (1996) *J. Mol. Graph.* **14**, 51–55
- Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) *Acta Crystallogr. A* **47**, 110–119
- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
- Casadaban, M., and Cohen, S. (1980) *J. Mol. Biol.* **138**, 179–207
- Lofberg, H., and Grubb, A. O. (1979) *Scand. J. Clin. Lab. Invest.* **39**, 619–626
- Olafsson, I., Lofberg, H., Abrahamson, M., and Grubb, A. (1988) *Scand. J. Clin. Lab. Invest.* **48**, 573–582
- Lindahl, P., Abrahamson, M., and Bjork, I. (1992) *Biochem. J.* **281**, 49–55
- Jeppson, J. O., Laurell, C. B., and Franzen, B. (1979) *Clin. Chem.* **25**, 629–638
- Laemmli, U. K. (1970) *Nature* **227**, 680–685
- Ritchie, R. F., and Smith, R. (1976) *Clin. Chem.* **22**, 497–499
- Abrahamson, M. (1994) *Methods Enzymol.* **244**, 685–700
- Nicklin, M. J., and Barrett, A. J. (1984) *Biochem. J.* **223**, 245–253
- Henderson, P. J. (1972) *Biochem. J.* **127**, 321–333
- Fernandez-Luna, J. L., Moneo, I., Grubb, A., and Mendez, E. (1985) *J. Immunol. Methods* **82**, 101–110
- Blumberg, S., Schechter, I., and Berger, A. (1970) *Eur. J. Biochem.* **15**, 97–102
- Glazer, A., and Smith, E. (1971) in *The Enzymes* (Boyer, P., ed) Vol. 3, pp. 501–546, Academic Press, Orlando
- LeVine, H., III (1993) *Protein Sci.* **2**, 404–410
- LeVine, H., III, and Scholten, J. D. (1999) *Methods Enzymol.* **309**, 467–476
- Dobson, C. M. (2003) *Nature* **426**, 884–889
- Wetzel, R. (2002) *Structure (Camb.)* **10**, 1031–1036
- Sipe, J. D., and Cohen, A. S. (2000) *J. Struct. Biol.* **130**, 88–98
- Booth, D. R., Sunde, M., Bellotti, V., Robinson, C. V., Hutchinson, W. L., Fraser, P. E., Hawkins, P. N., Dobson, C. M., Radford, S. E., Blake, C. C., and Pepys, M. B. (1997) *Nature* **385**, 787–793
- Ellis, R. J., and Pinheiro, T. J. (2002) *Nature* **416**, 483–484
- Newcomer, M. E. (2001) *Nat. Struct. Biol.* **8**, 282–284
- Bennett, M. J., Schlunegger, M. P., and Eisenberg, D. (1995) *Protein Sci.* **4**, 2455–2468
- Cohen, F. E., and Prusiner, S. B. (1998) *Annu. Rev. Biochem.* **67**, 793–819
- Klafki, H. W., Pick, A. I., Pardowitz, I., Cole, T., Awni, L. A., Barnikol, H. U., Mayer, F., Kratzin, H. D., and Hilschmann, N. (1993) *Biol. Chem. Hoppe Seyler* **374**, 1117–1122
- Schlunegger, M. P., Bennett, M. J., and Eisenberg, D. (1997) *Adv. Protein Chem.* **50**, 61–122
- Matsumura, M., Bechtel, W. J., Levitt, M., and Matthews, B. W. (1989) *Proc. Natl. Acad. Sci. U. S. A.* **86**, 6562–6566
- Futami, J., Tada, H., Seno, M., Ishikami, S., and Yamada, H. (2000) *J. Biochem. (Tokyo)* **128**, 245–250
- Zerovnik, E., Pompe-Novak, M., Skarabot, M., Ravnikar, M., Musevic, I., and Turk, V. (2002) *Biochim. Biophys. Acta* **1594**, 1–5
- Dobson, C. M. (1999) *Trends Biochem. Sci.* **24**, 329–332
- Lansbury, P. T., Jr. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96**, 3342–3344
- Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) *Nature* **416**, 535–539
- Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., and Stefani, M. (2002) *Nature* **416**, 507–511
- White, A. R., and Hawke, S. H. (2003) *J. Neurochem.* **87**, 801–808
- Ray, I., Chauhan, A., Wegiel, J., and Chauhan, V. P. S. (2000) *Brain Res.* **853**, 344–351
- McLaurin, J., Cecal, R., Kierstead, M. E., Tian, X., Phinney, A. L., Manea, M., French, J. E., Lambermon, M. H. L., Darabie, A. A., Brown, M. E., Janus, C., Chishti, M. A., Horne, P., Westaway, D., Fraser, P. E., Mount, H. T. J., Przybylski, M., and St. George-Hyslop, P. (2002) *Nat. Med.* **8**, 1263–1269
- Bjork, I., and Ylilinjarvi, K. (1989) *Biochem. J.* **260**, 61–68
- Baures, P. W., Oza, V. B., Peterson, S. A., and Kelly, J. W. (1999) *Bioorg. Med. Chem.* **7**, 1339–1347
- Pérez, M., Sadqi, M., Munoz, V., and Ávila, J. (2003) *Biochim. Biophys. Acta* **1639**, 133–139